Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2146 to 2160 of 9008 results

  1. Electrosurgery (diathermy and coblation) for tonsillectomy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Minimally invasive meshless and dissectionless anchoring system for pelvic organ prolapse repair

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Electrosurgery (diathermy and coblation) for tonsillectomy, (IP324/2)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. Actim Pancreatitis for diagnosing acute pancreatitis

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  5. Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. NVK-002 for treating myopia in people 3 to 17 years [TSID11961]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 28 April 2026.

    Technology appraisal guidance
    In consultation

  8. Reinforcement of a permanent stoma with synthetic or biological mesh to prevent a parastomal hernia

    Awaiting development Reference number: GID-HTG10678 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  9. Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Head injury (QS74) update: topic engagement

    We are listening to your views on this Quality standard. Comments close 30 April 2026.

    Quality standard
    In consultation

  12. Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]

    Awaiting development Reference number: GID-TA11594 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]

    Awaiting development Reference number: GID-TA11532 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development Reference number: GID-TA10446 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]

    In development Reference number: GID-TA10313 Expected publication date: TBC

    Technology appraisal guidance
    In development